Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the ...
Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...
A study presented at ACR Convergence 2025 has sparked interest among doctors and patients alike. Drugs originally made for ...
A daily pill to help people newly diagnosed with type 1 diabetes, or those at risk of developing it, live without the ...
A HIGH-VALUE individual (HVI) alias Alvin, 34, was arrested during a buy-bust operation executed by the Iloilo City Police ...
In the absence of much federal action, states have enacted dozens of laws this year to lower prescription drug costs for their residents — and many more are considering following suit. States cannot ...
MedPage Today on MSN
T-Cell Killer Opens New Approach to Rheumatoid Arthritis
Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...
GLP-1RA use was associated with a lower incidence of rheumatic diseases such as rheumatoid arthritis, gout, and ...
The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...
AnaptysBio (ANAB) announced late-breaking data from the robust, global 424-patient Phase 2b trial of rosnilimab, a selective and potent pathogenic ...
New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced ...
Treatment with TNF-α inhibitors may be safer than IL-6 inhibitors in terms of cardiovascular outcomes when managing patients with RA and T2D.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback